Northwestern University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Northwestern University sits in the top decile of US sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count).
Northwestern University: 1,209 sponsored US clinical trials, 187 recruiting.
Northwestern University sponsors 1,209 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 767 completed. 114 of these trials are in Phase 3-4 (later-stage) and 295 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 11 trials.
Top-decile sponsor footprint
Northwestern University ranks in the top decile of sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 912 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,209 total, page 22 of 25
T-Wave Alternans in Dialysis Patients
NCT00621426
Study of Light Treatment and Laser Treatment for Melasma
NCT00509977
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
NCT00392990
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
NCT00424242
Prospective Study of Ventral Hernia Repair
NCT00894582
Desensitization for Highly Sensitized Recipients of Pancreas Transplantation
NCT00867386
Activating Collaborative CIS Support Via Targeted Provider Mailing
NCT00873288
rHGH and Intestinal Permeability in Intestinal Failure
NCT01380366
Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata
NCT00791908
Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.
NCT00280527
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
NCT00369629
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
NCT00369707
Programmed Intermittent Epidural Bolus Time Interval and Injection Volume
NCT00417027
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
NCT00373672
Metabolic Syndrome in PCOS: Precursors and Interventions
NCT00442689
Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?
NCT00486902
Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
NCT00458003
Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
NCT00363038
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
NCT01015326
Accuracy of Blood Loss Estimation After Vaginal Delivery
NCT00462839
Quality of Life in Patients With Nonmelanoma Skin Cancer
NCT00518037
Oropharyngeal Function After Radiotherapy With IMRT
NCT00506324
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
NCT00711412
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
NCT00331630
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
NCT00316875
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
NCT00348790
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00334763
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
NCT00290706
Feasibility of a Partnered Approach to Prevent Diabetes
NCT00302055
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
NCT00306475
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
NCT00337207
Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)
NCT00866957
Reducing Risk Factors in Peripheral Arterial Disease
NCT00217919
D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
NCT00301080
Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
NCT01213329
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
NCT00288366
Dietary Supplementation With Soy Isoflavones in Asthma
NCT00277446
The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery
NCT00443560
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
NCT00288353
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
NCT00273364
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
NCT00276835
The Effect Of Light On Scar Appearance
NCT00544635
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
NCT00460174
Bevacizumab in Treating Patients With Angiosarcoma
NCT00288015
Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia
NCT00418015
Improving Communication With Patients With Breast Cancer
NCT00276822
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
NCT00867243
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
NCT00858117
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
NCT00278538
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
NCT00278525
What is open in the Northwestern University pipeline
187 recruiting of 1,209 indexed (15% open); 767 completed (63%).
Phase mix: 114 late (III/IV) vs 295 early (I/II) (early-phase heavy).
Top condition: Depression (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Northwestern University: open-pipeline peers nationwide
Peers matched on 1,209 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,209 trials (± recruiting share)
- Emory University · 1,208 trials · 17% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Brigham and Women's Hospital · 15% recruiting · 937 trials
- Incyte Corporation · 15% recruiting · 239 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Northwestern University page
1,209 registered trials is a research-attention snapshot, not an endorsement of Northwestern University or any single study.
- 187 of Northwestern University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Northwestern University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Northwestern University pipeline card: 1,209 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.